MEETINGS - Analytica 2000 (Germany) April 2000:
This article was originally published in Clinica
Analytica 2000, the 17th annual trade fair and conference for analysis, biotechnology, diagnostics and laboratory technology, will take place in Munich, Germany on April 11-14. The conference will include discussion on topics such as: genome analysis; nucleic acid chips (gene chips/genetic diagnostics); proteomics (functional protein analysis); protein expression; antibody engineering; molecular medicine; bioprocess control; bioanalysis in the bio-regions; bioanalysis in clinical pharmacy; biosensors; and bioanalysis and combinational chemistry. For more information contact the Analytica press office in Germany. Tel: +49 89 949 20670. Fax: +49 89 949 20679.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.